Table 1 Demographic data of 258 evaluated hormone receptor-positive patients
Clinicopathological parameter | Premenopausal (n = 67) | Postmenopausal (n = 191) | ||
|---|---|---|---|---|
n | % | n | % | |
Tumor stage | ||||
 I | 32 | 48 | 111 | 58 |
 II | 28 | 42 | 67 | 35 |
 III | 4 | 6 | 8 | 4 |
 IV | 0 | 0 | 0 | 0 |
 Unknown | 3 | 4 | 5 | 3 |
Subtype | ||||
 Invasive ductal | 56 | 84 | 151 | 79 |
 Invasive lobular | 7 | 10 | 24 | 13 |
 Others | 4 | 6 | 16 | 8 |
Grading | ||||
 1 | 5 | 7 | 25 | 13 |
 2 | 44 | 66 | 110 | 58 |
 3 | 17 | 25 | 52 | 27 |
 Unknown | 1 | 1 | 4 | 2 |
Lymph node status | ||||
 0 | 30 | 45 | 116 | 61 |
 1 | 19 | 28 | 52 | 27 |
 2 | 10 | 15 | 13 | 7 |
 3 | 6 | 9 | 6 | 3 |
 Unknown | 2 | 3 | 4 | 2 |
Endocrine treatment | ||||
 Tamoxifen | 43 | 64 | 66 | 35 |
 Aromatase inhibitor | 24 | 36 | 125 | 65 |
Surgery | ||||
 Mastectomy | 27 | 40 | 51 | 27 |
 Breast-conserving therapy | 40 | 60 | 140 | 73 |
Radiation | ||||
 Yes | 50 | 75 | 151 | 79 |
 No | 7 | 10 | 23 | 12 |
 Unknown | 10 | 15 | 17 | 9 |
Cytotoxicity treatment | ||||
 Yes | 56 | 84 | 85 | 44 |
 No | 1 | 1 | 3 | 2 |
 Unknown | 10 | 15 | 103 | 54 |